Institute Pasteur Paris

Paris, France

Institute Pasteur Paris

Paris, France

Time filter

Source Type

The invention relates to the quantitation of specific antibodies for at least one redox form of High mobility group box 1 (HMGB1) contained in a biological sample, in particular human serum and/or CerebroSpinal Fluid (CSF). The invention also relates to an in vitro method for assessing the state of progression of a disease or a disorder in which HMGB1 is involved, to an in vitro method for the identification of predisposition, prognostic or diagnostic biomarkers of a disease or a disorder in which HMGB1 is involved. The invention also relates to a kit to quantitate said specific antibodies for at least one redox form of HMGB1, in particular human HMGB1.


Patent
Institute Pasteur Paris and French National Center for Scientific Research | Date: 2017-01-18

The invention relates to building a chimeric polypeptide used for preventing or treating a Flaviviridae infection. The use of the inventive chimeric polypeptide for producing recombinant viral vectors such as a measles living viral vector is also disclosed.


Patent
Institute Pasteur Paris | Date: 2017-02-15

The invention relates to a new method for generating a luminescent signal, which is based on an enzyme-independent photon emission mechanism (EiPE), whereby luminescent light is generated when a bioluminescent substrate interact with a physical surface in the absence of any catalytic enzyme. In particular embodiments, the method is used to stimulate light emission by fluorescent molecules. The invention relates also to kits for implementing a method according to the present invention and to the use of a bioluminescent substrate, in the presence of a physical surface, to produce a luminescent signal in the absence of enzymatic catalyst.


A method for keeping leukocytes alive ex vivo or in vitro, comprising maintaining the leukocytes in a medium comprising from 3 to 10 mM of glucose, in hypoxic conditions with P(02) 10 mM Hg.


Patent
Institute Pasteur Paris and French National Center for Scientific Research | Date: 2017-02-27

The present invention relates to the use of variable domains of camelid heavy-chain antibodies (VHH domains) directed against an intracellular target and having an isoelectric point of at least 8.5, for targeting said intracellular target or for the preparation of a peptide vector. Particularly, it concerns VHH domains directed against a glial fibrillary acidic protein and uses thereof for preparing therapeutic or diagnostic agents.


The invention concerns stapled peptide inhibitors of NEMO which inhibit the Nuclear Factor B (NF-B) signaling pathway and are useful as medicine candidates, in particular as anti-inflammatory or anticancer drugs.


Patent
Institute Pasteur Paris | Date: 2017-07-19

The invention is in the domain of delivery of molecules to brain cells across the blood- brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of such carrier, including a model for testing the capacity of such molecule to cross the blood-brain barrier and / or the toxicity of molecules on the blood brain barrier and/or the capacity of molecules that have crossed to target human brain cells (e/g. neurons, astrocytes and microglial cells).


Patent
Institute Pasteur Paris | Date: 2017-07-19

The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of such carrier, including a model for testing the capacity of such molecule to cross the blood-brain barrier and/or the toxicity of molecules on the blood brain barrier and/or the capacity of molecules that have crossed to target human brain cells (e/g. neurons, astrocytes and microglial cells).


Patent
Institute Pasteur Paris | Date: 2017-08-09

The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding a) a secretion peptidic signal, b) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT, EC 2.1.1.63), a mutant or a catalytic domain thereof, and c) a recombinant protein. Said MGMT enzyme is preferably the so-called SNAP protein.


Etienne-Manneville S.,Institute Pasteur Paris
Annual Review of Cell and Developmental Biology | Year: 2013

Migration is a polarized cellular process that opposes a protrusive front edge to a retracting trailing edge. From the front to the rear, actin-mediated forces sequentially promote cell protrusion, adhesion, contraction, and retraction. Over the past decade, microtubules have revealed their pivotal role in cell migration. Through their roles in cell mechanics, intracellular trafficking, and signaling, microtubules participate in all essential events leading to cell migration. The front-rear polarization of microtubule functions relies on the asymmetric regulation of microtubule dynamics and stability; the asymmetric distribution of microtubule-associated protein complexes; and finally, the orientation of the microtubule network along the axis of migration. Microtubule network polarity controls the establishment and maintenance of the spatial and temporal coordination of migration events and is therefore the key to persistent directed migration. This review summarizes our current understanding of the functions of microtubules in persistent cell migration and of the migration-associated signals that promote microtubule network polarization. © 2013 by Annual Reviews. All rights reserved.

Loading Institute Pasteur Paris collaborators
Loading Institute Pasteur Paris collaborators